Dissertation > Excellent graduate degree dissertation topics show

The Research of Blocking EGFR and COX-2 Simultaneously to Treat NPC

Author: LiShiZuo
Tutor: TianYongQuan
School: Central South University
Course: Otolaryngology Head and Neck Surgery
Keywords: Nasopharyngeal EGFR COX-2 Targeted therapy
CLC: R739.63
Type: Master's thesis
Year: 2008
Downloads: 112
Quote: 1
Read: Download Dissertation

Abstract


The purpose of the epidermal growth factor receptor (epidermal growth factor receptor, EGFR) and cyclooxygenase -2 (Cyclooxygenase-2 and COX-2) of nasopharyngeal carcinoma development plays an important role. Developed EGFR inhibitors and COX-2 inhibitors and adjuvant therapy for radiotherapy has become the focus of attention. However, the efficacy of a single target in the treatment entirely satisfied. In this study, treatment with Tarceva (EGFR-tyrosine kinase antagonist) Joint C elecoxib (COX-2 inhibitors) nasopharyngeal carcinoma cell line CNE-1, CNE-2, observe the joint targeting therapy program for nasopharyngeal carcinoma cells the impact. With different concentrations of Tarceva (0-40umol / L) and C elecoxib (0-100umol by / L) deal with nasopharyngeal carcinoma cell line CNE-1, CNE-2, was observed by CCK-8 cell growth inhibition rate, determine the IC50. Then the concentration IC30 of Tarceva and c elecoxib, alone and combined treatment CNE-1, CNE-2 cells, compared to a separate processing and cell growth inhibition rate of the combined treatment. Analysis of cell cycle, apoptosis rate by flow cytometry, western blot detection related protein expression differences before and after drug treatment. The results (1) the Tarceva and C elecoxib treatment in CNE-1 and CNE-2 cells, a dose-dependent growth inhibition rate increased. Celecoxib treatment CNE-1 and CNE-2 cells the IC50 approximately 25umol / 1, Tarceva treatment the IC50 approximately 30umol CNE-1 cells / l processing CNE-2 cells the IC50 approximately 15umol / l. (2) CNE-1 cells combination of cell growth inhibition rate alone treated cells growth inhibition rate and the difference was not significant (P> 0.05). CNE-2 cells combined group of cell growth inhibition rate greater than the group rate of cell growth inhibition and separate treatment (P <0.05). (3) combined with the proportion of cells in the G1 phase of the treatment group than alone treatment group (P <0.05). The apoptosis rate of the combined treatment group apoptosis rate alone treated cells and compare the difference was not statistically significant (P> 0.05). (4) compared to the separate treatment group, the combination group apparent p-EGFR, reduced expression of COX-2. Conclusion (1) blocking the EGFR or COX-2 signaling pathway can inhibit nasopharyngeal carcinoma cell line CNE-1, CNE-2 growth, induction of apoptosis and cell cycle arrest in G1 phase. (2) Joint blocking EGFR and COX-2 signaling pathway to inhibit the growth of nasopharyngeal carcinoma cell line CNE-2 as well as to increase the G1 phase block, a synergistic effect. (3) Joint blocking EGFR and COX-2 signaling pathway has a synergistic effect in the inhibition of nasopharyngeal carcinoma cell line CNE-2 EGFR phosphorylation and COX-2 expression.

Related Dissertations

  1. Based on statistics of the lognormal distribution heteroscedasticity model inferred,O212.1
  2. The Study of Clinical Prognostic Factors in Nasopharyngeal Carcinoma after Intensity Modulated Radiation Therapy,R739.63
  3. Noble Dendrobium Polysaccharides Attenuate Learning and Memory Deficits Induced by Lipopolysaccharide and Its Mechanisms in Rats,R285.5
  4. The Feasibility of the Immunohistochemistry Classification to Predicting Prognosis in Breast Cancer,R737.9
  5. Sorafenib Treatment of Advanced Kidney Cancer Efficacy and Safety Evaluation,R737.11
  6. Protein Expressions of EGFR、K-ras、P53 and Ki-67 in Colorectal Cancer, Gastric Cancer and Esophageal Cancer,R735
  7. The Studies to Anti-tumor Effect and Its Mechanisms of Nsaids Combined with Sodium Butyrate on Human Colon Cancer Cell Line HCT-116 in Vitro,R735.35
  8. Ginsenoside Rg3 combined IRESSA on human A431 cell growth,R285.5
  9. Application Evaluation normal serum creatinine glomerular filtration rate in patients with chronic heart failure, renal function,R541.61
  10. The Comparative Analysis of Radiotherapeutic Prognosis of Nasopharyngeal Carcinoma According to Chinese 1992, 2008 and UICC2010 Staging Systems,R739.63
  11. Biodegradable Polymeric Drug Nano Carriers for Targeted Combinational Therapy of Cancers,R730.5
  12. Research on Synchronization Technology of Orthogonal Frequency Division Multiplexing System,TN919.3
  13. Inhibition of LRIG1 Gene in the Transfected GL15 Cell Line Affects the Expression of p-EGFR, p-AKT and p-ERK,R739.4
  14. The Expression of Hexokinase Ⅱ in Nasopharyngeal Carcinoma,R739.63
  15. Research on Effection and Mechanism of Radiosensitivity of Non-small Cell Lung Cancer Cell Line H358 Following Gefitinib Treatment,R734.2
  16. Expression of EGFR and ADAM9 in Pancreatic Cancer Panc-1 Cell Spheres,R735.9
  17. Aspirin-triggered Lipoxin Inhibit the Inflammatory Response Induced by Lipopolysaccharide in Primary Astrocytes,R965
  18. EGFR-JNK Signaling Pathway in Rat Glomerular Mesangial Cells Proliferation and Effect of Heparin on It,R965
  19. Preliminary Study on the Expression of Epidermal Growth Factor and Epidermal Growth Factor Receptor in Similar Clinical Stage But Different Prognosis Tongue Squamous Cell Carcinoma,R739.86
  20. Pre-emptive Analgesia Effect and Safety of Parecoxib Sodium in Patients Undergoing Maxillofacial Postoperative Analgesia,R782.054
  21. Relationship of Expression of VEGF and EGFR in Nasopharyngeal Carcinoma,R739.6

CLC: > Medicine, health > Oncology > Department of Otolaryngology tumor > Pharyngeal tumors
© 2012 www.DissertationTopic.Net  Mobile